Examkin

Question

Difficulty: MediumEnd-of-Life and Palliative Care

Emergency medical services bring a 79-year-old male to the emergency department due to severe shortness of breath. The patient has a known history of end-stage heart failure with reduced ejection fraction and stage 5 chronic kidney disease (baseline creatinine 3.9 mg/dL). Upon arrival, he is lethargic, obtunded, and incapable of meaningfully participating in his medical care. He exhibits profound respiratory distress with prominent use of accessory muscles.

His daughter accompanies him and provides the physician with legal documentation establishing her as the designated healthcare proxy, alongside a valid advance directive. The directive explicitly refuses endotracheal intubation and cardiopulmonary resuscitation, requesting only symptom-directed comfort care. Shortly thereafter, the patient's estranged son arrives. He becomes visibly upset, demanding that the patient be immediately intubated and transferred to the intensive care unit, threatening litigation if aggressive life-sustaining measures are withheld.

The attending physician concludes that intubation contradicts both the documented advance directive and the proxy's instructions. Meanwhile, the daughter urgently asks for medications to relieve her father's severe breathing difficulty.

Which of the following is the most appropriate next step in management?

  1. A
    Proceed with intubation and intensive care unit admission until the family disagreement is resolved
  2. B
    Request an emergency judicial review to determine the patient's legal competence to refuse intubation
  3. Administer low-dose intravenous hydromorphone and admit the patient for comfort-focused careAnswer
  4. D
    Administer intravenous ketorolac to relieve discomfort while avoiding the risk of respiratory depression
  5. E
    Arrange immediate transfer to a home hospice program without administering intravenous medications in the emergency department

Answer

Administer low-dose intravenous hydromorphone and admit the patient for comfort-focused care.
The most appropriate next step is to administer low-dose intravenous hydromorphone to relieve the patient's severe dyspnea and admit him for comfort-focused care. The patient lacks clinical decision-making capacity, so his legally designated healthcare proxy (the daughter) has the authority to direct his care. Her request aligns with the patient's valid advance directive, which refuses intubation. Therefore, the estranged son's demands must be respectfully declined. Furthermore, for managing dyspnea in a patient with severe chronic kidney disease, hydromorphone or fentanyl is preferred over morphine because morphine has active metabolites (e.g., morphine-6-glucuronide) that accumulate in renal failure and cause significant neurotoxicity.

Step-by-Step Solution

1
Assess the patient's clinical capacity to make medical decisions.
The patient is lethargic and obtunded, meaning he lacks the clinical capacity to direct his own care.
Establishing capacity determines whether the patient or a surrogate decision-maker has authority over current treatment choices.
2
Identify the legally appropriate surrogate decision-maker.
The daughter is the designated healthcare proxy and presents a valid advance directive.
A legally appointed healthcare proxy supersedes the wishes of other family members, such as the estranged son, within the surrogate hierarchy.
3
Select the appropriate pharmacological intervention for refractory dyspnea in the setting of severe renal impairment.
Intravenous hydromorphone is chosen to relieve distress.
Opioids are the treatment of choice for end-of-life dyspnea. Hydromorphone is preferred over morphine in stage 5 chronic kidney disease to prevent the accumulation of neurotoxic metabolites.

Key Concept

When a patient lacks clinical capacity, medical decisions are guided by their advance directive and legally designated healthcare proxy, superseding conflicting demands from other family members. Refractory dyspnea at the end of life is managed with opioids, utilizing agents like hydromorphone for patients with severe chronic kidney disease to avoid metabolite toxicity.
Estimated Time:1m 30s
Rate this question

Topics

End-of-Life and Palliative Care

More questions from this topic